IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have received a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $747.00.

A number of research analysts have issued reports on the stock. Citigroup upped their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Barclays decreased their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, UBS Group increased their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.79% of the company’s stock.

Hedge Funds Weigh In On IDEXX Laboratories

A number of hedge funds have recently made changes to their positions in the business. Harbour Investments Inc. increased its position in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after purchasing an additional 16 shares during the last quarter. Pinnacle Associates Ltd. lifted its stake in IDEXX Laboratories by 1.5% in the fourth quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock valued at $830,000 after acquiring an additional 18 shares during the last quarter. Triad Wealth Partners LLC lifted its stake in IDEXX Laboratories by 3.1% in the first quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock valued at $337,000 after acquiring an additional 18 shares during the last quarter. KCM Investment Advisors LLC grew its position in IDEXX Laboratories by 5.3% in the fourth quarter. KCM Investment Advisors LLC now owns 377 shares of the company’s stock worth $255,000 after acquiring an additional 19 shares in the last quarter. Finally, Arlington Trust Co LLC raised its holdings in shares of IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after purchasing an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 1.0%

Shares of IDXX stock opened at $509.56 on Thursday. The stock has a market cap of $40.14 billion, a P/E ratio of 35.83, a P/E/G ratio of 2.69 and a beta of 1.54. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. IDEXX Laboratories has a fifty-two week low of $500.61 and a fifty-two week high of $769.98. The business has a fifty day simple moving average of $554.49 and a 200-day simple moving average of $565.06.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, analysts forecast that IDEXX Laboratories will post 14.81 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.